Transcriptomics Technologies; Techniques Used To Study An Organism's Transcriptome
Transcriptomics Technologies |
Transcriptomics
Technologies are
techniques used to study an organism's transcriptome, the sum of all of its RNA
transcripts. The information of an organism is recorded in the DNA of its
genome and expressed through transcription. Transcriptomics is a comprehensive
analysis of whole sets of transcripts for the particular cell, tissue, organ,
or whole organism. Transcripts contain all types of RNA molecules, like
transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), and other
non-coding RNA molecules.
Two biological technologies, such as a
sequence-based approach (RNA-seq) and a hybridization-based technique (DNA
microarray) are used to study transcriptome. Transcriptomics
Technologies simultaneously obtain data from multiple transcripts
within a biological sample. Therefore, when a number of biological samples are
analyzed, large and complex data sets are generated to study the transcriptome.
The term
transcriptome can be used to describe the array of mRNA transcripts produced in
a particular cell or tissue type.
The Global
Transcriptomics Technologies Market Is Estimated To Account For US$
15,569.1 Mn In Terms Of Value By The End Of 2027.
Transcriptomics
Technologies use
high-throughput sequencing to identify and characterize a gene expression. They
can be used to profile the abundance of genes or to determine the structure of
the mRNA transcript, including 5' and 3' ends, start sites, and splice
junctions, and to analyze changes in gene expression over time. Transcriptomics
technologies have been used to study a wide range of genetic and biological
processes, such as cell division, protein synthesis, disease development, as
well as to discover novel therapeutic targets.
Transcriptomes of different disease
states, tissues, or even single cells are now routinely generated. This
explosion in transcriptomics has been driven by the rapid development of new
technologies with improved sensitivity and economy. In 2019,
Caris Life Sciences announced
that the U.S. Food and Drug Administration (FDA) has granted Breakthrough
Device designation for the company’s MI Transcriptome companion diagnostic
(CDx) test. The test is intended to help clinicians identify patients who may
benefit from treatment with specific targeted therapies.
Comments
Post a Comment